Understanding the Cardiovascular Benefits of the Anti-Diabetes Medication SGLT2 Inhibitors
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
To examine the effect of an increase in plasma beta-hydroxy-butyrate (B-OH-B) levels,
spanning the physiologic and pharmacologic range (+0.5, +2.0, and +5.0 mmol/L), on: (i)
parameters of left ventricular (LV) systolic and diastolic function utilizing cardiac
magnetic resonance imaging (MRI) and (ii) myocardial glucose uptake using positron emission
tomography (PET) with 18F-fluoro-2-deoxy-D-glucose in type 2 diabetic patients with Class
II-III New York Heart Association (NYHA).
Phase:
Phase 1
Details
Lead Sponsor:
The University of Texas Health Science Center at San Antonio